Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Michael Pulsipher, MD

    TitleProfessor of Pediatrics (Clinical Scholar)
    SchoolKeck School of Medicine of USC
    DepartmentPediatrics
    AddressCHLA 4650 W. Sunset Blvd.
    Off Campus
    Los Angeles California 90026
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P, Atta EH, Ayas M, Boelens JJ, Bonfim C, Deeg HJ, Kapoor N, Lee JW, Nakamura R, Pulsipher M, Eapen M, Antin JH. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017 Mar 24. PMID: 28341733.
        View in: PubMed
      2. Dietz AC, Mehta PA, Vlachos A, Savage SA, Bresters D, Tolar J, Boulad F, Dalle JH, Bonfim C, de la Fuente J, Duncan CN, Baker KS, Pulsipher M, Lipton JM, Wagner JE, Alter BP. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017 Jan 20. PMID: 28115275.
        View in: PubMed
      3. Heimall J, Puck J, Buckley R, Fleisher TA, Gennery AR, Neven B, Slatter M, Haddad E, Notarangelo LD, Baker KS, Dietz AC, Duncan C, Pulsipher M, Cowan MJ. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017 Jan 06. PMID: 28068510.
        View in: PubMed
      4. Shenoy S, Angelucci E, Arnold SD, Baker KS, Bhatia M, Bresters D, Dietz AC, De La Fuente J, Duncan C, Gaziev J, King AA, Pulsipher M, Smith A, Walters MC. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017 Jan 05. PMID: 28065838.
        View in: PubMed
      5. Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher M, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Treg Reconstitution and Does Not Prevent Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Dec 19. PMID: 28007665.
        View in: PubMed
      6. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher M. HRQoL among Older Related HSC Donors (>60 Yrs.) is Equivalent to That of Younger Related Donors (18-60 Yrs.): an RDSafe Study. Biol Blood Marrow Transplant. 2016 Oct 14. PMID: 27751935.
        View in: PubMed
      7. Dietz AC, Duncan CN, Alter BP, Bresters D, Cowan MJ, Notarangelo L, Rosenberg PS, Shenoy S, Skinner R, Walters MC, Wagner J, Baker KS, Pulsipher M. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation (HCT): Defining the Unique Late Effects of Children Undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant. 2016 Oct 10. PMID: 27737772.
        View in: PubMed
      8. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus HM, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher M, Gersten I, DiFronzo N, Horowitz MM, Walters MC, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24; 128(21):2561-2567. PMID: 27625358.
        View in: PubMed
      9. Armenian SH, Chemaitilly W, Chen M, Chow EJ, Duncan CN, Jones LW, Pulsipher M, Remaley AT, Rovo A, Salooja N, Battiwalla M. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. Biol Blood Marrow Transplant. 2016 Aug 30. PMID: 27590105.
        View in: PubMed
      10. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher M. Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. J Pediatr. 2016 Nov; 178:164-170.e1. PMID: 27522440.
        View in: PubMed
      11. Glenn JW, Cody MJ, McManus MP, Pulsipher M, Schiffman JD, Yost CC. Deficient Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplantation. Front Immunol. 2016; 7:250. PMID: 27446080.
        View in: PubMed
      12. Madden LM, Hayashi RJ, Chan KW, Pulsipher M, Douglas D, Hale GA, Chaudhury S, Haut P, Kasow KA, Gilman AL, Murray LM, Shenoy S. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016 Sep; 22(9):1734. PMID: 27343717.
        View in: PubMed
      13. Madden LM, Hayashi RJ, Chan KW, Pulsipher M, Douglas D, Hale GA, Chaudhury S, Haut P, Kasow KA, Gilman AL, Murray LM, Shenoy S. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016 Aug; 22(8):1467-72. PMID: 27164064.
        View in: PubMed
      14. Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher M, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transplant. 2016 Jul; 22(7):1197-205. PMID: 27040394.
        View in: PubMed
      15. Pulsipher M. Fishing for complements. Blood. 2016 Feb 25; 127(8):957-8. PMID: 26917734.
        View in: PubMed
      16. Wendler D, Shah NN, Pulsipher M, Fry T, Grady C. Research involving pediatric stem cell donors: A way forward. Clin Trials. 2016 Jun; 13(3):304-10. PMID: 26908544.
        View in: PubMed
      17. Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher M, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 May 1; 34(13):1537-43. PMID: 26884558.
        View in: PubMed
      18. Dietz AC, Lucchini G, Samarasinghe S, Pulsipher M. Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia. Curr Opin Pediatr. 2016 Feb; 28(1):3-11. PMID: 26626557.
        View in: PubMed
      19. Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher M, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 Jul; 57(7):1567-74. PMID: 26727639.
        View in: PubMed
      20. Nierkens S, Lankester AC, Egeler RM, Bader P, Locatelli F, Pulsipher M, Bollard CM, Boelens JJ. Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. Cytotherapy. 2015 Dec; 17(12):1667-74. PMID: 26589751.
        View in: PubMed
      21. Anthias C, O'Donnell PV, Kiefer DM, Yared J, Norkin M, Anderlini P, Savani BN, Diaz MA, Bitan M, Halter JP, Logan BR, Switzer GE, Pulsipher M, Confer DL, Shaw BE. European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. Biol Blood Marrow Transplant. 2016 Mar; 22(3):514-9. PMID: 26597079.
        View in: PubMed
      22. Anthias C, Shaw BE, Kiefer DM, Liesveld JL, Yared J, Kamble RT, D'Souza A, Hematti P, Seftel MD, Norkin M, DeFilipp Z, Kasow KA, Abidi MH, Savani BN, Shah NN, Anderlini P, Diaz MA, Malone AK, Halter JP, Lazarus HM, Logan BR, Switzer GE, Pulsipher M, Confer DL, O'Donnell PV. Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biol Blood Marrow Transplant. 2016 Mar; 22(3):520-7. PMID: 26597080.
        View in: PubMed
      23. Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher M, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep; 2(9):e367-75. PMID: 26685770.
        View in: PubMed
      24. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher M, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 2016 Feb; 22(2):248-57. PMID: 26327629.
        View in: PubMed
      25. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GM, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher M, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2154-9. PMID: 26327632.
        View in: PubMed
      26. Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, Shaw BE, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher M. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biol Blood Marrow Transplant. 2016 Jan; 22(1):96-103. PMID: 26307344.
        View in: PubMed
      27. Worel N, Buser A, Greinix HT, Hägglund H, Navarro W, Pulsipher M, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, Niederwieser D, van Walraven SM, Rocha V, Torosian T, Vergueiro C, Weisdorf D, Yabe H, Halter JP. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2052-60. PMID: 26271194.
        View in: PubMed
      28. Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher M, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015 Oct 15; 121(20):3709-16. PMID: 26207349.
        View in: PubMed
      29. Vaughn JE, Gooley T, Maziarz RT, Pulsipher M, Bhatia S, Maloney DG, Sandmaier BM, Flowers ME, Storb R, Sorror ML. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. Br J Haematol. 2015 Nov; 171(3):411-6. PMID: 26194447.
        View in: PubMed
      30. Shaw BE, Logan BR, Kiefer DM, Chitphakdithai P, Pedersen TL, Abdel-Azim H, Abidi MH, Akpek G, Diaz MA, Artz AS, Dandoy C, Gajewski JL, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Majhail NS, O'Donnell PV, Olsson RF, Savani BN, Schears RM, Stroncek DF, Switzer GE, Williams EP, Wingard JR, Wirk BM, Confer DL, Pulsipher M. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1830-8. PMID: 26116089.
        View in: PubMed
      31. ElSawy M, Storer BE, Pulsipher M, Maziarz RT, Bhatia S, Maris MB, Syrjala KL, Martin PJ, Maloney DG, Sandmaier BM, Storb R, Sorror ML. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015 Aug; 170(4):574-83. PMID: 25945807.
        View in: PubMed
      32. Pulsipher M, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, Kirsch I, Gastier-Foster JM, Borowitz M, Desmarais C, Williamson D, Kalos M, Grupp SA. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015 May 28; 125(22):3501-8. PMID: 25862561.
        View in: PubMed
      33. Pulsipher M. Long-term outcomes in MPS-IH: throwing stars. Blood. 2015 Mar 26; 125(13):2016-7. PMID: 25814488.
        View in: PubMed
      34. Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the science symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24. PMID: 25445636.
        View in: PubMed
      35. Hsu JW, Wingard JR, Logan BR, Chitphakdithai P, Akpek G, Anderlini P, Artz AS, Bredeson C, Goldstein S, Hale G, Hematti P, Joshi S, Kamble RT, Lazarus HM, O'Donnell PV, Pulsipher M, Savani BN, Schears RM, Shaw BE, Confer DL. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2015 Jan; 21(1):165-71. PMID: 25316111.
        View in: PubMed
      36. Yanik GA, Grupp SA, Pulsipher M, Levine JE, Schultz KR, Wall DA, Langholz B, Dvorak CC, Alangaden K, Goyal RK, White ES, Collura JM, Skeens MA, Eid S, Pierce EM, Cooke KR. TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015 Jan; 21(1):67-73. PMID: 25270958.
        View in: PubMed
      37. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher M, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014 Oct 10; 32(29):3249-56. PMID: 25154831.
        View in: PubMed
      38. Dvorak CC, Hassan A, Slatter MA, Hönig M, Lankester AC, Buckley RH, Pulsipher M, Davis JH, Güngör T, Gabriel M, Bleesing JH, Bunin N, Sedlacek P, Connelly JA, Crawford DF, Notarangelo LD, Pai SY, Hassid J, Veys P, Gennery AR, Cowan MJ. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Oct; 134(4):935-943.e15. PMID: 25109802.
        View in: PubMed
      39. Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher M, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica. 2014 Oct; 99(10):1624-31. PMID: 25085357.
        View in: PubMed
      40. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher M, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31; 371(5):434-46. PMID: 25075835.
        View in: PubMed
      41. Pulsipher M. Haplo is the new black. Blood. 2014 Jul 31; 124(5):675-6. PMID: 25082865.
        View in: PubMed
      42. Pulsipher M. Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes? Biol Blood Marrow Transplant. 2014 Oct; 20(10):1461-2. PMID: 25079876.
        View in: PubMed
      43. Lankester AC, Locatelli F, Bader P, Rettinger E, Egeler M, Katewa S, Pulsipher M, Nierkens S, Schultz K, Handgretinger R, Grupp SA, Boelens JJ, Bollard CM. Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant. 2015 Mar; 21(3):402-11. PMID: 25064748.
        View in: PubMed
      44. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher M, Maris MB, Davis C, Deeg HJ, Lee SJ, Maloney DG, Sandmaier BM, Appelbaum FR, Gooley TA. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014 Jul 10; 124(2):287-95. PMID: 24797298.
        View in: PubMed
      45. Anderson HM, Wilkes J, Korgenski EK, Pulsipher M, Blaschke AJ, Hersh AL, Srivastava R, Bonkowsky JL. Preventable Infections in Children with Leukodystrophy. Ann Clin Transl Neurol. 2014 May 1; 1(5):370-374. PMID: 24955379.
        View in: PubMed
      46. Pulsipher M, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP, Shaw BE, O'Donnell PV, Majhail NS, Confer DL. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood. 2014 Jun 5; 123(23):3655-63. PMID: 24735965.
        View in: PubMed
      47. Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 2014 May 29; 123(22):3504-11. PMID: 24711663.
        View in: PubMed
      48. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher M, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ. Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8. PMID: 24641829.
        View in: PubMed
      49. Pulsipher M, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, Raetz E, Gardner S, Gastier-Foster JM, Howrie D, Goyal RK, Douglas JG, Borowitz M, Barnes Y, Teachey DT, Taylor C, Grupp SA. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014 Mar 27; 123(13):2017-25. PMID: 24497539.
        View in: PubMed
      50. Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, McManus MP, Pulsipher M, Yandell M, Bohnsack JF, Jorde LB, Notarangelo LD, Walter JE. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014 Mar; 133(3):880-2.e10. PMID: 24472623.
        View in: PubMed
      51. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher M, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014 Mar 6; 123(10):1615-20. PMID: 24435046.
        View in: PubMed
      52. Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher M, Smith FO, Zhang MJ, Eapen M, Carpenter PA. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2014 Jun; 61(6):1126-8. PMID: 24391118.
        View in: PubMed
      53. Schultz RK, Baker KS, Boelens JJ, Bollard CM, Egeler RM, Cowan M, Ladenstein R, Lankester A, Locatelli F, Lawitschka A, Levine JE, Loh M, Nemecek E, Niemeyer C, Prasad VK, Rocha V, Shenoy S, Strahm B, Veys P, Wall D, Bader P, Grupp SA, Pulsipher M, Peters C. Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1279-87. PMID: 23883618.
        View in: PubMed
      54. Shereck E, Shenoy S, Pulsipher M, Burns L, Bracey A, Chell J, Snyder E, Nemecek E. Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1399-402. PMID: 23838095.
        View in: PubMed
      55. Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher M, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct; 33(7):1156-64. PMID: 23818196.
        View in: PubMed
      56. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher M, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1340-7. PMID: 23769990.
        View in: PubMed
      57. Pulsipher M. Better BMT for Hurler syndrome--on the level? Blood. 2013 May 9; 121(19):3785-7. PMID: 23660858.
        View in: PubMed
      58. Savage SA, Pulsipher M, Romano A, Berlyne D. Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012. Leuk Res. 2013 Jul; 37(7):848-51. PMID: 23643149.
        View in: PubMed
      59. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher M, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013 Apr 20; 31(12):1530-8. PMID: 23478054.
        View in: PubMed
      60. Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher M, Smith FO, Zhang MJ, Eapen M, Carpenter PA. Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biol Blood Marrow Transplant. 2013 Jun; 19(6):893-7. PMID: 23467128.
        View in: PubMed
      61. Goyal RK, Han K, Wall DA, Pulsipher M, Bunin N, Grupp SA, Mada SR, Venkataramanan R. Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. Biol Blood Marrow Transplant. 2013 Apr; 19(4):569-75. PMID: 23266742.
        View in: PubMed
      62. Grupp SA, Dvorak CC, Nieder ML, Levine JE, Wall DA, Langholz B, Pulsipher M. Children's Oncology Group's 2013 blueprint for research: stem cell transplantation. Pediatr Blood Cancer. 2013 Jun; 60(6):1044-7. PMID: 23255402.
        View in: PubMed
      63. Pulsipher M, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, O'Donnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013 Jan 3; 121(1):197-206. PMID: 23109243.
        View in: PubMed
      64. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher M, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct 18; 367(16):1487-96. PMID: 23075175.
        View in: PubMed
      65. Navarro WH, Switzer GE, Pulsipher M. National marrow donor program session: donor issues. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S15-9. PMID: 23085601.
        View in: PubMed
      66. Pulsipher M. Pediatric-specific guidelines for fever and neutropenia: a catalyst for improving care and focusing research. J Clin Oncol. 2012 Dec 10; 30(35):4292-3. PMID: 23045574.
        View in: PubMed
      67. Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher M, Difronzo NL, Confer DL, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul; 18(7):1007-11. PMID: 22546497.
        View in: PubMed
      68. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher M, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012 Jul; 18(7):979-81. PMID: 22490784.
        View in: PubMed
      69. Pulsipher M. A donor's a person, no matter how small. Blood. 2012 Mar 22; 119(12):2705-6. PMID: 22442334.
        View in: PubMed
      70. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012 Apr 26; 119(17):4083-90. PMID: 22408257.
        View in: PubMed
      71. Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher M, Sande J, Schultz KR, Spellman S, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012 Aug; 18(8):1265-72. PMID: 22343376.
        View in: PubMed
      72. Pulsipher M, Skinner R, McDonald GB, Hingorani S, Armenian SH, Cooke KR, Gracia C, Petryk A, Bhatia S, Bunin N, Nieder ML, Dvorak CC, Sung L, Sanders JE, Kurtzberg J, Baker KS. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant. 2012 Mar; 18(3):334-47. PMID: 22248713.
        View in: PubMed
      73. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher M, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012 Apr; 18(4):505-22. PMID: 22209888.
        View in: PubMed
      74. Parsons SK, Phipps S, Sung L, Baker KS, Pulsipher M, Ness KK. NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant. 2012 Feb; 18(2):162-71. PMID: 22155139.
        View in: PubMed
      75. Bunin N, Small T, Szabolcs P, Baker KS, Pulsipher M, Torgerson T. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors. Biol Blood Marrow Transplant. 2012 Jan; 18(1):6-15. PMID: 22100979.
        View in: PubMed
      76. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher M, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011 Nov 2; 306(17):1874-83. PMID: 22045765.
        View in: PubMed
      77. Dvorak CC, Gracia CR, Sanders JE, Cheng EY, Baker KS, Pulsipher M, Petryk A. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1725-38. PMID: 22005649.
        View in: PubMed
      78. Nieder ML, McDonald GB, Kida A, Hingorani S, Armenian SH, Cooke KR, Pulsipher M, Baker KS. National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1573-84. PMID: 21963877.
        View in: PubMed
      79. Bhatia S, Davies SM, Scott Baker K, Pulsipher M, Hansen JA. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1428-35. PMID: 21763253.
        View in: PubMed
      80. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher M. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011 Jul; 96(7):942-7. PMID: 21719883.
        View in: PubMed
      81. Baker KS, Bhatia S, Bunin N, Nieder M, Dvorak CC, Sung L, Sanders JE, Kurtzberg J, Pulsipher M. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1424-7. PMID: 21723224.
        View in: PubMed
      82. Nemecek ER, Ellis K, He W, Bunin NJ, Bajwa RS, Cheerva A, Cairo MS, Dvorak C, Duval M, Davies S, Eapen M, Gross TG, Hussein AA, MacMillan ML, Mehta PA, Pulsipher M, Seber A, Woolfrey AE, Frangoul HA, Carpenter PA. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1833-40. PMID: 21683798.
        View in: PubMed
      83. Pulsipher M. There's more to surviving transplant than remission. Pediatr Blood Cancer. 2011 Sep; 57(3):359-60. PMID: 21618416.
        View in: PubMed
      84. Pulsipher M, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S137-48. PMID: 21195303.
        View in: PubMed
      85. Pulsipher M, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011 Mar; 17(3):291-9. PMID: 21034841.
        View in: PubMed
      86. Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher M. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010 Nov 11; 116(19):4007-15. PMID: 20671124.
        View in: PubMed
      87. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher M, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010 Jun 10; 28(17):2859-67. PMID: 20439626.
        View in: PubMed
      88. O'Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher M, Stroncek D, Leitman S, Anderlini P. Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood. 2010 Jun 17; 115(24):5097-101. PMID: 20228276.
        View in: PubMed
      89. Pulsipher M, Horwitz EM, Haight AE, Kadota R, Chen AR, Frangoul H, Cooper LJ, Jacobsohn DA, Goyal RK, Mitchell D, Nieder ML, Yanik G, Cowan MJ, Soni S, Gardner S, Shenoy S, Taylor D, Cairo M, Schultz KR. Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1212-21. PMID: 20079865.
        View in: PubMed
      90. Nakamae H, Storer BE, Storb R, Storek J, Chauncey TR, Pulsipher M, Petersen FB, Wade JC, Maris MB, Bruno B, Panse J, Petersdorf E, Woolfrey A, Maloney DG, Sandmaier BM. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol Blood Marrow Transplant. 2010 Mar; 16(3):384-94. PMID: 19900571.
        View in: PubMed
      91. Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher M, Haut PR, Schultz KR, Taylor DS, Frangoul HA. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1620-7. PMID: 19896086.
        View in: PubMed
      92. Pulsipher M, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol. 2009 Dec; 147(5):691-9. PMID: 19744131.
        View in: PubMed
      93. Pulsipher M, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, Horowitz MM, Miller JP, King RJ, Confer DL. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009 Sep 24; 114(13):2606-16. PMID: 19608747.
        View in: PubMed
      94. Pulsipher M, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood. 2009 Aug 13; 114(7):1429-36. PMID: 19528536.
        View in: PubMed
      95. Pulsipher M. Maintenance loses its innocence. Blood. 2009 Jun 11; 113(24):6041-2. PMID: 19520809.
        View in: PubMed
      96. Pulsipher M, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, Klein JP, Horowitz MM, Confer DL. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009 Apr 9; 113(15):3604-11. PMID: 19190248.
        View in: PubMed
      97. Pulsipher M, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):62-71. PMID: 19147081.
        View in: PubMed
      98. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher M, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009 Apr 2; 113(14):3383-91. PMID: 19015394.
        View in: PubMed
      99. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG, Niederwieser DW, Bruno B, Maziarz RT, Pulsipher M, Petersen FB, Storb R, Fuchs EJ, Maloney DG. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87. PMID: 18940683.
        View in: PubMed
      100. Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher M, McSweeney PA, Wade JC, Bruno B, Langston A, Radich J, Niederwieser D, Blume KG, Storb R, Maloney DG. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008 Oct 20; 26(30):4912-20. PMID: 18794548.
        View in: PubMed
      101. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, Maziarz RT, Pulsipher M, McSweeney PA, Storb R. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008 May 1; 112(9):1992-2001. PMID: 18311781.
        View in: PubMed
      102. Bratton SL, Van Duker H, Statler KD, Pulsipher M, McArthur J, Keenan HT. Lower hospital mortality and complications after pediatric hematopoietic stem cell transplantation. Crit Care Med. 2008 Mar; 36(3):923-7. PMID: 18091550.
        View in: PubMed
      103. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey T, Forman SJ, Lange T, Shizuru J, Langston A, Pulsipher M, Sandmaier BM, Storb R, Maloney DG. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008 Jan 10; 26(2):211-7. PMID: 18056679.
        View in: PubMed
      104. Frangoul H, Nemecek ER, Billheimer D, Pulsipher M, Khan S, Woolfrey A, Manes B, Cole C, Walters MC, Ayas M, Ravindranath Y, Levine JE, Grupp SA. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood. 2007 Dec 15; 110(13):4584-7. PMID: 17827386.
        View in: PubMed
      105. Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney D. Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2007 Aug; 48(8):1482-95. PMID: 17701578.
        View in: PubMed
      106. Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T, Petersdorf E, Bethge W, Maziarz RT, McSweeney PA, Pulsipher M, Wade JC, Chauncey TR, Shizuru JA, Sorror ML, Woolfrey AE, Maloney DG, Storb R. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1041-8. PMID: 17697966.
        View in: PubMed
      107. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B, Langston A, Pulsipher M, McSweeney PA, Wade JC, Epner E, Bo Petersen F, Bethge WA, Maloney DG, Storb R. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007 Oct 1; 110(7):2744-8. PMID: 17595333.
        View in: PubMed
      108. Wendland MM, Smith DC, Boucher KM, Asch JD, Pulsipher M, Thomson JW, Shrieve DC, Gaffney DK. The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Am J Clin Oncol. 2007 Apr; 30(2):156-62. PMID: 17414465.
        View in: PubMed
      109. Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher M, Chauncey TR, Mielcarek M, Storer BE, Storb R. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant. 2007 Apr; 13(4):423-32. PMID: 17287157.
        View in: PubMed
      110. Phillips JD, Steensma DP, Pulsipher M, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007 Mar 15; 109(6):2618-21. PMID: 17148589.
        View in: PubMed
      111. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher M, Agura ED, Wade J, Sorror M, Maloney DG, Sandmaier BM. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006 Sep 1; 24(25):4150-7. PMID: 16896000.
        View in: PubMed
      112. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6. PMID: 16782928.
        View in: PubMed
      113. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006 Apr; 12(4):454-65. PMID: 16545729.
        View in: PubMed
      114. Pulsipher M, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006 Apr; 46(4):422-33. PMID: 16411207.
        View in: PubMed
      115. Grupp SA, Frangoul H, Wall D, Pulsipher M, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer. 2006 Apr; 46(4):414-21. PMID: 16463346.
        View in: PubMed
      116. Wendland MM, Asch JD, Pulsipher M, Thomson JW, Shrieve DC, Gaffney DK. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol. 2006 Apr; 29(2):189-95. PMID: 16601441.
        View in: PubMed
      117. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher M, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006 Jan 1; 24(1):145-51. PMID: 16382124.
        View in: PubMed
      118. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1; 23(16):3819-29. PMID: 15809448.
        View in: PubMed
      119. Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA, Radich JP, Pulsipher M, Agura ED, Chauncey TR, Maloney DG, Shizuru JA, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005 Apr; 11(4):272-9. PMID: 15812392.
        View in: PubMed
      120. Pulsipher M. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer. 2004 Oct; 43(5):523-33. PMID: 15382266.
        View in: PubMed
      121. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M, Storb R, Maloney DG. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004 Dec 1; 104(12):3535-42. PMID: 15304387.
        View in: PubMed
      122. Ford CD, Asch J, Pulsipher M, Petersen FB. Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia. Br J Haematol. 2004 Aug; 126(4):623-4. PMID: 15287959.
        View in: PubMed
      123. Kurre P, Pulsipher M, Woolfrey A, Maris M, Sandmaier B, Kiem HP, Storb R. Reduced toxicity and prompt engraftment after minimal conditioning of a patient with Fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matched unrelated donor. J Pediatr Hematol Oncol. 2003 Jul; 25(7):581-3. PMID: 12847331.
        View in: PubMed
      124. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003 Sep 15; 102(6):2021-30. PMID: 12791654.
        View in: PubMed
      125. Feinstein LC, Sandmaier BM, Maloney DG, Maris MB, Gooley TA, Chauncey TR, Hegenbart U, McSweeney PA, Stuart MJ, Forman SJ, Agura EA, Pulsipher M, Blume KG, Niederwieser DW, Storb RF. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant. 2003 Apr; 9(4):266-72. PMID: 12720219.
        View in: PubMed
      126. Woolfrey AE, Pulsipher M, Storb R. Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children. Int J Hematol. 2002 Aug; 76 Suppl 2:271-7. PMID: 12430936.
        View in: PubMed
      127. Georges GE, Maris M, Sandmaier BM, Malone DG, Feinstein L, Niederweiser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, Little MT, Sahebi F, Hegenbart U, Pulsipher M, Bruno B, Forman S, Woolfrey AE, Radich JP, Blume KG, Storb R. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol. 2002 Aug; 76 Suppl 1:184-9. PMID: 12430851.
        View in: PubMed